Skip to content

Orciprenaline

beta2-Adrenergic Agonist — RESPIRATORY SYSTEM

Also known as: metaproterenol, metaproterenol sulfate, orciprenaline sulfate

OfpFDA approvedATC R03AB03ATC R03CB03ATC R03CB53

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Orciprenaline is an ofp drug in the beta2-Adrenergic Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1973. Its mechanism of action is classified as Adrenergic beta2-Agonists. DrugCentral lists 2 molecular targets, including ADRB2 and ADRB2. Recorded indications include Acute exacerbation of asthma, Asthma, Asthma management and Bronchitis.

  • Approval status: ofp (first approved 1973 by the FDA).
  • Drug class: beta2-Adrenergic Agonist.
  • Mechanism of action: Adrenergic beta2-Agonists.
  • Molecular targets: ADRB2 and ADRB2 (2 listed in DrugCentral).
  • Indications: Acute exacerbation of asthma, Asthma, Asthma management, Bronchitis and Bronchospasm Prevention and others.
  • ATC code: R03AB03 (Non-selective beta-adrenoreceptor agonists).
  • Molecular formula: C11H17NO3; molecular weight 211.26 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

  • Acute exacerbation of asthma
  • Asthma
  • Asthma management
  • Bronchitis
  • Bronchospasm Prevention
  • Pulmonary emphysema

Contraindications (8)

  • Chronic heart failure
  • Diabetes mellitus
  • Disorder of coronary artery
  • Hypertensive disorder
  • Hyperthyroidism
  • Myocardial ischemia
  • Seizure disorder
  • Tachyarrhythmia

Mechanism & targets

Mechanism of action (MoA)Adrenergic beta2-Agonists
Established pharmacologic classbeta2-Adrenergic Agonist

Molecular targets (2)

TargetGeneActionActivity
Beta-2 adrenergic receptorADRB2agonistKd 6.30
Beta-2 adrenergic receptorADRB2unknownKd 5.04

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1973-07-31FDA——

ATC classification

ATC codeTherapeutic hierarchy
R03AB03RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Non-selective beta-adrenoreceptor agonists
R03CB03RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS FOR SYSTEMIC USE › Non-selective beta-adrenoreceptor agonists
R03CB53RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS FOR SYSTEMIC USE › Non-selective beta-adrenoreceptor agonists

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Orciprenaline is on its molecule page.

Molecular formulaC11H17NO3
Molecular weight211.26 g/mol
CAS number586-06-1
InChIKeyLMOINURANNBYCM-UHFFFAOYSA-N
PubChem CID4086
CC(C)NCC(O)C1=CC(O)=CC(O)=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Orciprenaline used for?

DrugCentral lists the following indications for Orciprenaline: Acute exacerbation of asthma, Asthma, Asthma management, Bronchitis, Bronchospasm Prevention and Pulmonary emphysema.

How does Orciprenaline work?

Orciprenaline is classified as Adrenergic beta2-Agonists; its molecular targets in DrugCentral include ADRB2 (agonist) and ADRB2.

When was Orciprenaline first approved?

Orciprenaline was first approved by the FDA in 1973.

What drug class does Orciprenaline belong to?

Orciprenaline is in the beta2-Adrenergic Agonist class.

What is the chemical formula of Orciprenaline?

Orciprenaline has the molecular formula C11H17NO3 and a molecular weight of 211.26 g/mol.

Browse: all drugs starting with O · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1973-07-31
AgencyFDA
Targets2
Indications6
FormulaC11H17NO3
DrugCentral ID1720
Interactive profile